Given the key role of angiogenesis in tumor growth and metastasis [62,63,64], and the highly vascular nature of glioblastomas [97], anti-angiogenic drugs, particularly those that target VEGF, have been extensively explored as management options [90]. This evidence concerns the gene VEGFA and neoplasm.